SLS 241220 2.00P (SLS241220P2000) Stock Options, News & Quotes

US OptionsDetailed Quotes

SLS241220P2000

Watchlist

0.95
+0.05+5.56%

15min DelayClose Nov 27 16:00 ET

0.95High0.95Low

Intraday

5D
Daily

News

SELLAS Life Sciences Group Identifies ASXL1 Mutations as Predictive Biomarkers for SLS009 Efficacy in Solid Cancers
BarchartNov 27 18:52 ET
Express News | Sellas Shares up 3.8% After Co Reports Preclinical Data for Blood Cancer Drug
ReutersNov 27 10:25 ET
Sellas Life Sciences Announces Data From Preclinical Studies of SLS009
TipRanksNov 27 08:50 ET
Express News | Sellas: Asxl1 Mutations Predictably Identified in Colorectal Cancer and Non-Small Cell Lung Cancer in Addition to Hematologic Malignancies
ReutersNov 27 08:46 ET
Express News | Sellas Life Sciences Group Inc: Preselection Method for Cancers Responding to Sls009
ReutersNov 27 08:45 ET
Express News | Sellas Announces Positive Data From Preclinical Studies Indicating Asxl1 Mutations as Predictor of Response to Sls009 in Solid Cancers
ReutersNov 27 08:45 ET

Comments

Trytosaveabit

Nov 27 07:50

Update

$Sellas Life Sciences (SLS.US)$ Reuters· 2 mins ago
Sellas: Asxl1 Mutations Predictably Identified in Colorectal Cancer and Non-Small Cell Lung Cancer in Addition to Hematologic Malignancies

Jaguar8

Nov 27 07:46

NEWS

$Sellas Life Sciences (SLS.US)$
SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers
1 minute ago, 5:45 AM PST
Via GlobeNewswire
- Preselection Method for Cancers Responding to SLS009: High Efficacy of SLS009 Observed in 67% of ASXL1 Mutated Solid Cancers vs 0% in Non-ASXL1 Mutated Cancers –
- ASXL1 Mutations Predictably Identified in Colorectal Cancer (CRC MSI-H) and Non-Small Cell Lung Cancer (NSCLC) in Add...

steven smith38

Oct 15 07:58

$Sellas Life Sciences (SLS.US)$ try in the houseeeee

Trytosaveabit

Oct 15 07:47

News

$Sellas Life Sciences (SLS.US)$ Reuters· 1 min ago
Sellas Announces U.S. FDA Rare Pediatric Disease Designation (Rpdd) Granted to Galinpepimut-S (Gps) for the Treatment of Pediatric Acute Myeloid Leukemia

Jaguar8

Oct 15 07:45

NEWS

$Sellas Life Sciences (SLS.US)$
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia
SELLAS Life Sciences Group (NASDAQ: SLS) has received Rare Pediatric Disease Designation (RPDD) from the FDA for Galinpepimut-S (GPS) in treating pediatric acute myeloid leukemia (AML). GPS, an immunotherapeutic targeting Wilms Tumor-1, is currently in a Phase 3 REGAL trial for adult AML patients, with an inte...